NASDAQ:REUN Reunion Neuroscience (REUN) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free REUN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.12▼$1.1250-Day Range$1.11▼$1.1352-Week Range$0.63▼$5.07VolumeN/AAverage Volume210,209 shsMarket Capitalization$13.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Reunion Neuroscience alerts: Email Address Ad Schaeffer’s ResearchJust Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.Yes! Show Me This Strategy About Reunion Neuroscience Stock (NASDAQ:REUN)Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.Read More Ad Schaeffer’s ResearchJust Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.Yes! Show Me This Strategy REUN Stock News HeadlinesApril 9, 2024 | au.lifestyle.yahoo.comAs AI accelerates, Europe's flagship privacy principles are under attack, warns EDPSApril 9, 2024 | time.comWhat Experts Really Think About Diet SodaApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 3, 2024 | globenewswire.comReunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 ConferenceMarch 14, 2024 | msn.comThe life of '73 Oak Ridge High grad Robin Wallace, Part 1March 12, 2024 | msn.comThe Perks of YearningFebruary 22, 2024 | forbes.comThe Sloan Research Fellows For 2024 Have Been AnnouncedFebruary 4, 2024 | ca.news.yahoo.comBritish documentary producer Isabelle Lawrence Thomas dies aged 39April 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… January 14, 2024 | msn.comNeuroscientists find the importance of dopamine in relationships through rodent studyJanuary 12, 2024 | msn.comA biological signature of desire helps explain the selective nature of pair bondsNovember 25, 2023 | forbes.comGet Behavior Change That Lasts Using NeuroscienceNovember 14, 2023 | investing.comReunion Neuroscience (REUN) Earnings Dates & ReportsNovember 13, 2023 | mirror.co.ukMatthew Perry sparked concern as warning signs were spotted during 2021 Friends reunionNovember 12, 2023 | dailymail.co.ukSo much for Mickey Mouse degrees! How students graduating from polytechnics in courses you've never heard of earn higher salaries than their peersOctober 24, 2023 | usnews.comBest Global Universities for Neuroscience and BehaviorOctober 5, 2023 | finance.yahoo.comReunion Neuroscience Inc. to Participate in October Investor ConferencesSeptember 23, 2023 | dallasnews.comHeart disease survivors reflect at American Heart Association’s annual walk in DallasAugust 14, 2023 | markets.businessinsider.comPsyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & MoreAugust 3, 2023 | theglobeandmail.comClosing Bell: Reunion Neuroscience Inc flat on Friday (REUN)August 3, 2023 | benzinga.comReunion Neuroscience Completes Take-Private Setup: Delisting & Consideration DetailsJuly 17, 2023 | msn.comReunion Neuroscience On The Brink Of Going Private With Final Court ApprovalJuly 14, 2023 | financialpost.comReunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of ArrangementJune 29, 2023 | msn.comReunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3June 29, 2023 | finanznachrichten.deReunion Neuroscience Inc.: Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateJune 29, 2023 | msn.comReunion Neuroscience: Q4 Earnings InsightsJune 29, 2023 | msn.comRecap: Reunion Neuroscience Q4 EarningsSee More Headlines Receive REUN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryN/A Current SymbolNASDAQ:REUN CUSIPN/A CIK1865482 Webwww.reunionneuro.com Phone1-833-222-0084Fax1-855-933-1211Employees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,690,000.00 Net MarginsN/A Pretax Margin-2,583.10% Return on Equity-91.82% Return on Assets-64.58% Debt Debt-to-Equity RatioN/A Current Ratio3.51 Quick Ratio3.51 Sales & Book Value Annual Sales$3.88 million Price / Sales3.38 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book0.82Miscellaneous Outstanding Shares11,720,000Free FloatN/AMarket Cap$13.13 million OptionableNot Optionable Beta2.29 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Hannan Fleiman (Age 42)Co-Founder & Non-Independent Director Comp: $214.69kDr. Nathan Bryson B.Sc. (Age 59)Ph.D., Chief Science Officer Comp: $312.47kMr. Gregory T. Mayes Esq. (Age 54)J.D., Pres, CEO & Director Mr. Edward F. Smith CPA (Age 52)Chief Financial Officer Mr. Curtis WeberGen. CounselMr. Stephan CoteHead of QualityDr. Robert Alexander M.D.Chief Medical Officer & Sr. AdvisorMore ExecutivesKey CompetitorsUpHealthNYSE:UPHLAgape ATPNASDAQ:ATPCPear TherapeuticsNASDAQ:PEAREUDA HealthNASDAQ:EUDATonix PharmaceuticalsNASDAQ:TNXPView All Competitors REUN Stock Analysis - Frequently Asked Questions Should I buy or sell Reunion Neuroscience stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reunion Neuroscience in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REUN shares. View REUN analyst ratings or view top-rated stocks. This page (NASDAQ:REUN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reunion Neuroscience Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
